Pharmaceutical Executive-12-01-2017

Pharm Exec details the latest approaches to combating disease and health crises on a global scale-including industry perspectives from those involved on the front lines.

Amid a widening net of health threats worldwide, alliances forged in research and response may be more critical than ever to stem the tide.

FDA's approval of the first-ever digital medicine, while sparking legitimate concerns around ethics and trust, could signal improvements ahead to the much-chronicled woes in drug adherence and compliance.

Figuring out the right formula to address global health-for the better.

In 2017, patients gained access to the first gene therapies and more orphan and breakthrough drugs.

Groundbreaking treatment approaches call for innovative commercialization strategies.

New action plan urges tighter alignment of public health policy with the development of targeted therapies.

Drawing from his research roots and the leadership lessons gained in melding business and culture in geographies across the globe, Ruud Dobber is busy steering AstraZeneca’s US course as it navigates the complexities of a fast-evolving therapeutic market.

Despite having the tenth-largest pharma market in the world and being the birthplace of medical breakthroughs, from insulin to stem cells, Canada seems to be punching below its weight when it comes to health innovation. There are signs, however, that things may be changing as the nation looks to bulk back up.

Click the title above to open the Pharmaceutical Executive December 2017 issue in an interactive PDF format.